WH announces 9 new agreements with pharma manufacturers aimed at slashing prescription drug costs for Americans

US President Donald Trump shakes hands with Richard Ascroft, CEO North America of Sun Pharma, during an announcement on Healthcare Affordability in the Oval Office of the White House in Washington, DC on August 31, 2026.

In a major policy milestone for healthcare reform, President Donald Trump announced nine new agreements with pharmaceutical manufacturers aimed at slashing prescription drug costs for Americans.

Under these voluntary deals, manufacturers agree to align U.S. drug pricing with the lowest prices paid by other developed countries, a framework known as the most-favored-nation (MFN) price model. The latest expansion brings the total roster of pharmaceutical companies participating in MFN pricing to 26, collectively representing roughly 89% of the domestic branded drug market.

The nine newly added mid-sized manufacturers include Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB. 

Their addition “extends price caps across a broad spectrum of critical treatment categories, spanning oncology, hemophilia, Parkinson’s disease, macular degeneration, glaucoma, and chronic dermatological conditions,” according to the White House.

 

Officials emphasize that every state Medicaid program nationwide will immediately gain access to MFN pricing for these manufacturers’ products, yielding billions in aggregate public savings while closing structural loopholes that previously permitted foreign nations to leverage U.S. drug innovation at lower costs.

Beyond direct price reductions, the newly signed agreements tie international market access to substantial investments in domestic healthcare infrastructure.

The nine manufacturers have collectively pledged at least $19.6 billion in near-term U.S. manufacturing investments and agreed to donate significant quantities of essential active pharmaceutical ingredients (APIs) — including crucial antibiotics, anticonvulsants, and immunosuppressants — to the Strategic Active Pharmaceutical Ingredients Reserve to safeguard national drug supply chains against foreign disruptions.

 

Building on initial executive actions and major manufacturer deals signed since last year, the GOP administration continues to position the MFN program alongside its direct-to-consumer TrumpRx platform as the cornerstone of its drug affordability strategy.

The administration projects broader statutory MFN rules and foreign pricing negotiations will generate up to $600 billion in domestic health savings over the coming decade.

Simultaneously, President Trump also renewed calls for Congress to pass the Great Healthcare Plan to permanently codify MFN protections into federal law.

 

President Trump says Americans are now paying the lowest prescription drug prices in the world after his administration secured major price cuts.

Trump says drug costs have already fallen and could drop by as much as 80%, calling it a historic achievement that he says deserves… pic.twitter.com/BlRl94Rrxu

— One America News (@OANN) August 31, 2026